GO:0001806 type IV hypersensitivity: T Cell-Mediated Inflammation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001806 (type IV hypersensitivity) is defined as an inflammatory response driven by T cell recognition of processed soluble or cell-associated antigens leading to cytokine release and leukocyte activation.
• It is also known as delayed-type hypersensitivity (DTH) and is classified as a delayed, T cell-mediated hypersensitivity reaction distinct from immediate antibody-mediated types.
• The reaction typically peaks 24-72 hours after antigen exposure and involves antigen presentation, T cell activation, cytokine secretion, and macrophage/leukocyte recruitment.
• Common clinical triggers include metals (gold, nickel), restorative dental materials, drugs, and cyanoacrylate-based medical adhesives.
• Diagnostic approaches include patch testing, delayed reading of intradermal tests, and clinical correlation; management centers on allergen identification and avoidance.
• Research models span animal studies, human patch test cohorts, and quantitative risk assessment frameworks for ingredient safety.
Description
Type IV hypersensitivity (GO:0001806) is a biological process defined as an inflammatory response driven by T cell recognition of processed soluble or cell-associated antigens leading to cytokine release and leukocyte activation. Unlike the immediate hypersensitivity reactions (types I-III) that are mediated by antibodies, type IV is a delayed, cell-mediated response that depends on antigen-specific T lymphocytes and typically becomes clinically apparent 24-72 hours after antigen exposure. This delay reflects the time required for antigen processing, T cell priming, cytokine production, and the recruitment of effector leukocytes to the site of antigen challenge. The term is synonymous with delayed hypersensitivity response and delayed-type hypersensitivity (DTH).
type IV hypersensitivity At A Glance
| GO ID | GO:0001806 |
|---|---|
| GO term | type IV hypersensitivity |
| Ontology | biological_process |
| Synonym | delayed hypersensitivity response; delayed-type hypersensitivity |
| Major function | T cell-mediated inflammatory response to processed antigens with cytokine release and leukocyte activation |
| Cellular players | T lymphocytes, antigen-presenting cells, macrophages, and other leukocytes |
| Typical timing | Delayed onset, usually 24-72 hours after antigen exposure |
| Clinical examples | Contact dermatitis, drug hypersensitivity, reactions to metals and restorative materials |
| Diagnostic approach | Patch testing, delayed intradermal reading, clinical correlation |
What Is GO:0001806?
Type IV hypersensitivity is a T cell-mediated inflammatory process in which processed soluble or cell-associated antigens are recognized by T lymphocytes, leading to cytokine release and activation of leukocytes. It is a delayed response, in contrast to antibody-mediated immediate hypersensitivity, and encompasses several subtypes including contact, tuberculin, granulomatous, and Jones-Mote reactions. The QuickGO definition emphasizes the central role of T cell recognition and the downstream cytokine-driven leukocyte activation that characterizes this biological process.
Why Is type IV hypersensitivity Important in Cell Biology?
Type IV hypersensitivity is clinically important because it underlies many common and potentially severe inflammatory conditions, including contact dermatitis, drug hypersensitivity reactions, and reactions to implanted materials. Understanding this process is essential for diagnosing delayed hypersensitivity, identifying causative agents, and developing safer materials and therapeutics. In biomedical research, GO:0001806 provides a framework for studying T cell-mediated inflammation, cytokine biology, and leukocyte recruitment, with relevance to allergy, immunology, dermatology, and implant biocompatibility.
• Explains delayed inflammatory reactions to metals such as gold and nickel in medical and dental devices.
• Underlies contact dermatitis and patch-test-positive reactions to restorative materials.
• Contributes to drug hypersensitivity reactions, including severe cutaneous adverse reactions.
• Relevant to reactions to cyanoacrylate venous closure and other medical adhesives.
• Provides a mechanistic basis for T cell-mediated tissue inflammation and cytokine release.
• Guides safety assessment of ingredients used in veterinary and human products.
• Supports development of in vitro and in vivo models for delayed hypersensitivity.
• Helps distinguish type IV from immediate hypersensitivity in clinical diagnosis.
• Informs allergen avoidance and management strategies in affected patients.
• Facilitates research on leukocyte activation and macrophage recruitment in delayed responses.
What Happens During type IV hypersensitivity?
Antigen Processing and Presentation
In simple terms: The immune system takes up the trigger substance and shows pieces of it to T cells.
In type IV hypersensitivity, soluble or cell-associated antigens are processed by antigen-presenting cells and presented to T lymphocytes. This step is required for T cell recognition and is a defining feature of the delayed response. The antigens can be derived from metals, drugs, or other environmental agents.
T Cell Activation and Cytokine Release
In simple terms: T cells recognize the antigen and release signals that call other immune cells.
Upon recognition of processed antigen, T cells become activated and release cytokines. This cytokine release is a central event in the QuickGO definition and drives the subsequent inflammatory cascade. The cytokines then activate and recruit leukocytes to the site.
Leukocyte Recruitment and Activation
In simple terms: Immune cells rush to the area and become active, causing inflammation.
Cytokines produced by activated T cells lead to leukocyte activation and recruitment. This phase accounts for the clinical signs of inflammation, such as redness, swelling, and induration, which typically appear 24-72 hours after antigen exposure. Macrophages and other leukocytes are key effector cells in this process.
Delayed Clinical Manifestation
In simple terms: The reaction takes one to three days to show up because it needs time to build.
The delayed nature of type IV hypersensitivity distinguishes it from immediate reactions. Clinical examples include contact dermatitis and reactions to gold weight implants or cyanoacrylate venous closure, where symptoms appear hours to days after exposure. Patch testing exploits this delay by reading results at 48-72 hours.
Subtypes of Type IV Hypersensitivity
In simple terms: There are different flavors of this delayed reaction depending on the cells and timing involved.
Type IV hypersensitivity includes subtypes such as contact, tuberculin, granulomatous, and Jones-Mote reactions. Each subtype involves different T cell populations and cytokine profiles, but all share the core feature of T cell-mediated inflammation. This heterogeneity is important for interpreting clinical and experimental findings.
Key Genes Involved in GO:0001806 type IV hypersensitivity
The following genes and proteins are central to the T cell-mediated inflammation, cytokine signaling, and leukocyte activation that define type IV hypersensitivity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD4 | T helper cell co-receptor for MHC class II antigen recognition | Marker of T cells involved in delayed hypersensitivity |
| CD8 | Cytotoxic T cell co-receptor for MHC class I antigen recognition | Participates in some type IV subtypes |
| IFNG | Cytokine that activates macrophages and promotes inflammation | Key effector cytokine in delayed-type hypersensitivity |
| TNF | Pro-inflammatory cytokine that amplifies leukocyte recruitment | Contributes to tissue inflammation in type IV reactions |
| IL2 | T cell growth factor that supports clonal expansion | Drives T cell activation in delayed responses |
| IL4 | Cytokine influencing T helper cell differentiation | Modulates type IV reaction subtypes |
| IL12 | Cytokine promoting Th1 differentiation | Supports cell-mediated immunity in type IV |
| IL17 | Cytokine involved in neutrophil recruitment | Contributes to inflammatory cascades |
| CCL2 | Chemokine that recruits monocytes/macrophages | Mediates leukocyte recruitment in DTH |
| CXCL8 | Chemokine that recruits neutrophils | Amplifies leukocyte activation |
| ICAM1 | Adhesion molecule for leukocyte extravasation | Facilitates leukocyte recruitment to inflamed tissue |
| VCAM1 | Adhesion molecule for leukocyte adhesion | Supports leukocyte infiltration in delayed responses |
| HLA-DRA | MHC class II antigen presentation | Presents processed antigens to CD4+ T cells |
| HLA-A | MHC class I antigen presentation | Presents antigens to CD8+ T cells |
| TLR4 | Pattern recognition receptor for innate immune activation | Can amplify antigen presentation and inflammation |
| NLRP3 | Inflammasome sensor that promotes IL-1beta release | Links innate immunity to type IV inflammation |
| PTGS2 | Cyclooxygenase-2 enzyme in prostaglandin synthesis | Contributes to inflammatory mediator production |
How Is type IV hypersensitivity Regulated?
Type IV hypersensitivity is regulated by a balance of T helper cell subsets and their cytokine profiles. Th1 cells, characterized by IFN-gamma production, are classically associated with delayed-type hypersensitivity, while other subsets such as Th17 and regulatory T cells modulate the intensity and duration of the response. Cytokine signaling through pathways such as IL-12/STAT4 and IL-4/STAT6 influences T cell differentiation and the resulting inflammatory outcome. Regulatory mechanisms also include negative feedback by anti-inflammatory cytokines and checkpoint molecules, which limit tissue damage.
type IV hypersensitivity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNG | Delayed-type hypersensitivity and macrophage activation | Ifng knockout mouse with antigen challenge |
| CD4 | T cell-mediated contact dermatitis | CD4 knockout mouse in contact hypersensitivity model |
| HLA-DRA | Antigen presentation in drug hypersensitivity | HLA-DRA transgenic or knock-in cell lines |
| CCL2 | Leukocyte recruitment in delayed inflammation | Ccl2 knockout mouse in DTH model |
| NLRP3 | Inflammasome-mediated inflammation | Nlrp3 knockout macrophages with antigen stimulation |
Contact Dermatitis and Material Hypersensitivity
Type IV hypersensitivity is the underlying mechanism of allergic contact dermatitis, including reactions to metals such as gold and nickel, and to restorative dental materials. Patients typically present with delayed onset of eczema, swelling, or induration at the site of contact, and patch testing is used to identify the culprit allergen. Management involves allergen avoidance and topical or systemic anti-inflammatory therapy.
Drug Hypersensitivity Reactions
Delayed drug hypersensitivity reactions are a significant clinical problem and can range from mild maculopapular exanthema to severe cutaneous adverse reactions. These reactions are T cell-mediated and fit the definition of type IV hypersensitivity. Diagnosis relies on clinical history, skin testing, and sometimes patch testing, while treatment requires withdrawal of the offending drug and supportive care.
Reactions to Medical Devices and Implants
Type IV hypersensitivity can occur after implantation of medical devices, such as gold weight eyelid implants or cyanoacrylate venous closure. Symptoms may include localized inflammation, swelling, or delayed wound healing. Recognition of the delayed immune response is important for appropriate device selection and patient management.
Veterinary and Safety Assessment Applications
Type IV hypersensitivity is also studied in veterinary medicine and in quantitative risk assessment for ingredients used on animals. Animal models of delayed hypersensitivity help evaluate the sensitization potential of chemicals and pharmaceuticals. These assessments inform safety guidelines and product development.
From type IV hypersensitivity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene drive T cell activation in type IV hypersensitivity? | Knockout mouse or human T cell line with CRISPR KO |
| Does a point mutation in a cytokine gene alter delayed response? | Point-mutation knock-in cell model |
| Can a reporter track T cell activation in real time? | Tagged knock-in of fluorescent reporter at endogenous locus |
| Does overexpression of a chemokine enhance leukocyte recruitment? | Overexpression cell line or transgenic mouse |
| Which genes regulate antigen presentation in delayed hypersensitivity? | CRISPR library screening in antigen-presenting cells |
| Can humanized models recapitulate drug-induced type IV reactions? | Humanized mouse or iPSC-derived immune cells |
How to Study the type IV hypersensitivity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch testing | Delayed skin inflammation to contactants | Diagnosis of allergic contact dermatitis |
| Intradermal test with delayed reading | T cell-mediated local response | Evaluation of drug or antigen hypersensitivity |
| Animal DTH model | In vivo delayed inflammatory response | Mechanistic and safety studies |
| Flow cytometry | T cell activation and cytokine production | Characterization of immune cell subsets |
| ELISA/ELISpot | Cytokine secretion by T cells | Quantification of IFN-gamma and other cytokines |
| Quantitative risk assessment | Sensitization potential of ingredients | Safety evaluation for veterinary products |
| Immunohistochemistry | Leukocyte infiltration in tissue | Analysis of delayed hypersensitivity lesions |
| CRISPR screening | Genes regulating T cell activation | Discovery of novel modulators of type IV hypersensitivity |
Patch Testing and Clinical Assessment
Patch testing is a standard method to diagnose type IV hypersensitivity to contactants, with readings typically performed at 48-72 hours. It measures delayed inflammatory skin reactions and helps identify causative allergens in dental materials and metals. Clinical correlation is essential for accurate interpretation.
Animal Models of Delayed Hypersensitivity
Animal models, including mice and guinea pigs, are used to study type I and type IV hypersensitivity. These models allow controlled antigen exposure and measurement of delayed inflammatory responses, such as ear swelling or footpad induration. They are valuable for mechanistic studies and safety assessment.
Cellular and Molecular Assays
In vitro assays using T cells, antigen-presenting cells, and macrophages can measure cytokine release, proliferation, and activation markers. Flow cytometry, ELISA, and ELISpot are commonly used to quantify T cell responses. These methods help dissect the molecular pathways of type IV hypersensitivity.
Quantitative Risk Assessment
Quantitative risk assessment frameworks have been applied to evaluate the sensitization potential of ingredients, including for canine products. These approaches integrate exposure and potency data to estimate the likelihood of type IV hypersensitivity. They support regulatory and product safety decisions.
How CRISPR Can Be Used to Study GO:0001806 type IV hypersensitivity
Knockout
CRISPR knockout of candidate genes in T cells or antigen-presenting cells can test their requirement for type IV hypersensitivity responses. For example, knocking out IFNG or CD4 can reduce delayed inflammatory responses in cellular models. These experiments help establish causal roles in the pathway.
Point Mutation
Point mutations can be introduced to model naturally occurring variants or to dissect specific residues in cytokine or receptor genes. Such models are useful for understanding how subtle genetic changes affect T cell activation and cytokine release. They complement knockout studies by revealing domain-specific functions.
Knock-in
Knock-in of reporter genes or humanized alleles allows tracking of T cell activation and antigen presentation in real time. Tagged knock-in models can also be used to study protein localization and interactions during delayed hypersensitivity. These approaches provide dynamic insights into the process.
Overexpression
Overexpression of cytokines or chemokines in cell lines or animal models can enhance leukocyte recruitment and inflammation, mimicking aspects of type IV hypersensitivity. Such models help test whether a gene is sufficient to drive the response. They are valuable for validating therapeutic targets.
How EDITGENE Supports type IV hypersensitivity Research
Researchers studying type IV hypersensitivity-related genes often need to determine whether a candidate gene is causally involved in T cell activation, cytokine release, or leukocyte recruitment. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for type IV hypersensitivity research.
Frequently Asked Questions About type IV hypersensitivity
What is type IV hypersensitivity?
Type IV hypersensitivity is a delayed, T cell-mediated inflammatory response to processed antigens, leading to cytokine release and leukocyte activation.
What genes are involved in type IV hypersensitivity?
Key genes include IFNG, TNF, IL2, CD4, CD8, and chemokines such as CCL2, which mediate T cell activation and leukocyte recruitment.
What is the difference between type IV and other hypersensitivity reactions?
Type IV is cell-mediated and delayed, whereas types I-III are antibody-mediated and immediate.
How is type IV hypersensitivity diagnosed?
Diagnosis often involves patch testing or delayed intradermal reading, along with clinical history.
What are common triggers of type IV hypersensitivity?
Common triggers include metals like gold and nickel, dental restorative materials, drugs, and cyanoacrylate adhesives.
What is delayed-type hypersensitivity (DTH)?
DTH is a synonym for type IV hypersensitivity, emphasizing the delayed onset of the T cell-mediated response.
Can type IV hypersensitivity be prevented?
Prevention focuses on identifying and avoiding the causative allergen, as well as using safer materials.
What animal models are used to study type IV hypersensitivity?
Animal models such as mice and guinea pigs are used to study delayed hypersensitivity responses.
How does CRISPR help study type IV hypersensitivity?
CRISPR enables knockout, knock-in, and point-mutation models to test gene function in T cell activation and inflammation.
What is the role of cytokines in type IV hypersensitivity?
Cytokines such as IFN-gamma and TNF are released by activated T cells and drive leukocyte activation and recruitment.
Conclusion
Type IV hypersensitivity (GO:0001806) is a fundamental biological process in immunology, defined by T cell recognition of processed antigens and subsequent cytokine-mediated leukocyte activation. Its clinical relevance spans contact dermatitis, drug hypersensitivity, and reactions to medical materials, making it a key area for both diagnostic and therapeutic research. Understanding the genes and mechanisms involved provides a foundation for developing targeted interventions and safer products.
References
- 1. Almeida TFA et al.. 2022. Type IV hypersensitivity associated with restorative materials: Clinical report and systematic literature review.. J Prosthet Dent 128(6):1201-1210 PMID: 33820631
- 2. Wilkerson RG. 2023. Drug Hypersensitivity Reactions.. Immunol Allergy Clin North Am 43(3):473-489 PMID: 37394254
- 3. Czarnobilska E et al.. 2007. [Type IV of hypersensitivity and its subtypes].. Przegl Lek 64(7-8):506-8 PMID: 18409354
- 4. Uzzaman A et al.. 2012. Chapter 28: Classification of hypersensitivity reactions.. Allergy Asthma Proc 33 Suppl 1:96-99 PMID: 22794701
- 5. O'Banion LAA et al.. 2023. Type IV Hypersensitivity Reaction after Cyanoacrylate Venous Closure.. Ann Vasc Surg 95:218-223 PMID: 37301253
- 6. Kilduff CLS et al.. 2018. Type IV Hypersensitivity to Gold Weight Upper-Eyelid Implant: Case Report and Review of the Literature.. Ocul Immunol Inflamm 26(6):910-914 PMID: 28471252
- 7. Schultz KT. 1982. Type I and type IV hypersensitivity in animals.. J Am Vet Med Assoc 181(10):1083-7 PMID: 6217177
- 8. McDermott A et al.. 2025. Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines.. Vet Med Sci 11(4):e70463 PMID: 40536915
